Hemochromatosis - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Hemochromatosis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Hemochromatosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Companies Mentioned

  • Ionis Pharmaceuticals Inc
  • La Jolla Pharmaceutical Company
  • Protagonist Therapeutics Inc
  • Silence Therapeutics Plc
  • Vifor Pharma AG

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Hemochromatosis - Overview
  4. Hemochromatosis - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Hemochromatosis - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Hemochromatosis - Companies Involved in Therapeutics Development
  16. Ionis Pharmaceuticals Inc
  17. La Jolla Pharmaceutical Company
  18. Protagonist Therapeutics Inc
  19. Silence Therapeutics Plc
  20. Vifor Pharma AG
  21. Hemochromatosis - Drug Profiles
  22. BBI-001 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. IONISTMPRSS-6LRx - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. LJPC-401 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. NSC-8679 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. PTG-300 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. SLN-124 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. VIT-2763 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. Hemochromatosis - Dormant Projects
  55. Hemochromatosis - Product Development Milestones
  56. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/hsvkxc/hemochromatosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs